SCHEDULE: Vanguard Group Reports 0% Stake in Twist Bioscience

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Twist Bioscience Corp following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 5 to Schedule 13G for Twist Bioscience Corp.
• The filing indicates that The Vanguard Group now beneficially owns 0 shares, representing 0% of the class of Common Stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of Vanguard will report beneficial ownership separately.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over these securities, in accordance with SEC Release No. 34-39538.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Twist Bioscience Corp, as it primarily reflects an internal reporting adjustment by The Vanguard Group rather than a change in investment position or company performance.

Industry Context

StockSavvy.ai notes that this filing reflects an internal organizational change within The Vanguard Group rather than a strategic investment decision regarding Twist Bioscience Corp. Such realignments are common among large asset managers for operational or regulatory compliance purposes and typically do not signal a change in investment thesis for the underlying company.

Stakeholder Impact

• Shareholders of Twist Bioscience Corp: No direct impact on company operations or value, but a change in the reported institutional ownership structure by a major fund manager.

Key Dates

Keywords

Twist Bioscience Corp, Vanguard Group, Schedule 13G, beneficial ownership, common stock, SEC filing, institutional ownership, internal realignment